SCHEMBL796952

SCHEMBL796952

[CH2]c1cccc(OCC)c1OCC

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.45
L3MBTL1 Q9Y468 7/20 0.41
MAPT P10636 3/20 0.41
LMNA P02545 2/20 0.41
KDM4E B2RXH2 2/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
POLB P06746 1/20 0.41
GAA P10253 1/20 0.41
RECQL P46063 1/20 0.41
NPSR1 Q6W5P4 1/20 0.40
GLA P06280 1/20 0.40
HTR1A P08908 1/20 0.40
ADRA1D P25100 1/20 0.40
ADRA1A P35348 1/20 0.40
ADRA1B P35368 1/20 0.40
CHRM2 P08172 2/20 0.39
CHRM1 P11229 1/20 0.39
ALOX15 P16050 1/20 0.39
TSHR P16473 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16958647 0.89 CHRM2 (0.42) ALDH1A1L3MBTL1MAPTLMNAKDM4E
SCHEMBL10981497 0.88 ALDH1A1 (0.42) ALDH1A1L3MBTL1MAPTLMNAKDM4E
SCHEMBL10980213 0.88 SMN1; SMN2 (0.52) ALDH1A1L3MBTL1MAPTKDM4EMEN1
SCHEMBL27436345 0.84 HTR1A (0.56) ALDH1A1L3MBTL1MAPTLMNAMEN1
SCHEMBL2068454 0.84 ALDH1A1 (0.54) ALDH1A1L3MBTL1MAPTLMNAKDM4E
SCHEMBL16959324 0.83 NPSR1 (0.38) ALDH1A1L3MBTL1MAPTLMNAKDM4E
SCHEMBL16955203 0.82 L3MBTL1 (0.39) ALDH1A1L3MBTL1MAPTLMNAKDM4E
SCHEMBL16961864 0.82 MEN1 (0.43) ALDH1A1L3MBTL1MAPTLMNAKDM4E
SCHEMBL16960643 0.82 L3MBTL1 (0.36) ALDH1A1L3MBTL1MAPTLMNAKDM4E
SCHEMBL973269 0.81 ALDH1A1 (0.41) ALDH1A1L3MBTL1MAPTKDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 113 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3575281-B1 DIAMINE COMPOUND, AND POLYIMIDE COMPOUND AND MOLDED ARTICLE IN WHICH SAID DIAMINE COMPOUND IS USED WINGO TECH CO LTD (JP) 2023-08-23 EP claimed
EP-2363390-A1 DERIVED LACTAM FROM D3 VITAMIN Teijin Pharma Limited (JP) 2011-09-07 EP claimed
US-20110207944-A1 VITAMIN D3 LACTAM DERIVATIVE TEIJIN PHARMA LIMITED (JP) 2011-08-25 US claimed
CN-118176259-A Dispersion of carbon nanotubes, coating liquid composition for electrode using same, electrode, and lithium ion secondary battery 第一工业制药株式会社 2024-06-11 CN disclosed
CN-117866200-A Polybenzoxazole precursor, process for producing the same, and photosensitive resin composition 上海交通大学 2024-04-12 CN disclosed
EP-3575281-B1 DIAMINE COMPOUND, AND POLYIMIDE COMPOUND AND MOLDED ARTICLE IN WHICH SAID DIAMINE COMPOUND IS USED WINGO TECH CO LTD (JP) 2023-08-23 EP disclosed
CN-113518792-B Polybenzoxazole precursor containing ester diamine, photosensitive resin composition, dry film, cured product, and electronic component 太阳控股株式会社 2023-08-15 CN disclosed
WO-2023080059-A1 DISPERSION OF CARBON NANOTUBES, COATING LIQUID COMPOSITION FOR ELECTRODE USING SAME, ELECTRODE, AND LITHIUM ION SECONDARY BATTERY 第一工業製薬株式会社 2023-05-11 WO disclosed
CN-111770951-B Polyimide compound and molded article comprising same 胜高科技股份有限公司 2023-04-11 CN disclosed
US-20220162445-A1 POLYIMIDE COMPOUND AND MOLDED ARTICLE COMPRISING THE POLYIMIDE COMPOUND WINGO TECHNOLOGY CO., LTD. (JP) 2022-05-26 US disclosed
EP-3919548-A1 POLYIMIDE COMPOUND AND MOLDED ARTICLE CONTAINING SAID POLYIMIDE COMPOUND Wingo Technology Co., Ltd. (JP) 2021-12-08 EP disclosed
US-4864021-A ANTICARCINOGENIC AGENTS, ANTITUMOR AGENTS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1989-09-05 US disclosed
EP-0323441-A2 5-Fluorouracil derivatives OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1989-07-05 EP disclosed
US-4727073-A CEREBOVASCULAR DISEASES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1988-02-23 US disclosed
US-4678792-A ANTITHROMBIC AGENTS DR. KARL THOMAE GMBH (DE) 1987-07-07 US disclosed
EP-0223245-A2 Curable compositions for dental drugs having sustained release property MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) 1987-05-27 EP disclosed
EP-0180897-A2 5-Fluorouracil derivatives OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1986-05-14 EP disclosed
EP-0180188-A2 A composition for increasing the anti-cancer activity of an anti-cancer compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1986-05-07 EP disclosed
EP-0177287-A2 Pyrimidine derivatives, processes for preparation thereof and composition of the same FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1986-04-09 EP disclosed
US-4497815-A 1-(N-Substituted carbamoyl)-5-fluorouracil derivatives and the carcinostatic agents containing same as active ingredients Ozaki, Shoichiro (JP) 1985-02-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110207944-A1 VITAMIN D3 LACTAM DERIVATIVE VDR, CYP24A1, CYP2R1 ALDH1A1 1894/4885L3MBTL1 763/4885MAPT 2111/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.